RecruitingNCT05640700
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
Assessing Personalized Vaginal Microbiome Contributions to HPV-driven Pre-malignant and Malignant Cervical Cancer
Sponsor
Hadassah Medical Organization
Enrollment
90 participants
Start Date
Nov 9, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
In this study, the investigators will prospectively collect, analyze and integrate information regarding vaginal microbiome composition and HPV presence in women with cervical pathologies (high-grade CIN and CC) and controls, to construct a large dataset from patients with pre-cancerous cervical lesions and healthy women, to evaluate the personalized contribution of the vaginal microbiome to the CIN-CC sequence.
Eligibility
Sex: FEMALEMin Age: 25 YearsMax Age: 70 Years
Inclusion Criteria2
- Age 25-70
- Attended the clinic for a Pap smear or colposcopy
Exclusion Criteria5
- Patient does not approve sample collection
- Usage of antibiotics in the month prior to clinic visit
- Usage of any vaginal preparation or medication in the week prior to sample collection (anti-fungal, spermicides, lubricant etc.)
- Menstruation
- Pregnancy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05640700
Related Trials
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
NCT054915127 locations
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
NCT051088701 location
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
NCT057745611 location
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
NCT0549590610 locations
PopSci CHW4CervixHealth
NCT073361341 location